Research at the Day Lab
Cecil B. Day Laboratory for Neuromuscular Research
The Angel Fund for ALS Research supports the ALS research at the Cecil B. Day Laboratory for Neuromuscular Research at UMass Medical School in Worcester, MA. The lab is under the direction of Dr. Robert H. Brown, Jr.
Dept of Neurology at UMass Medical School
Research update – July 2018
As you may know, last summer we treated a single ALS patient on a compassionate use basis using a new gene therapy approach aimed at silencing the SOD1 gene, from which we have learned a great deal. The results from that first patient have now embolden us to treat a second patient, also on a compassionate use basis, which we hope will happen soon.
The first patient was treated at UMass Memorial Medical Center in Worcester; this second patient will be treated in Boston at Mass General Hospital under the care of my longtime collaborator, Dr. Merit Cudkowicz. We have evolved the protocol for the second patient based on what we learned from the first, providing us with high hopes and expectations for further success. If we do see strong progress with the second patient, that hopefully will trigger a plan to launch an expanded access, Phase I trial that will treat approximately 10 additional patients.
I also am pleased to announce a new partnership with a biotech start-up, called Apic Bio, a novel gene therapy company that was spun-out of UMass Medical School. Together with your generous support, Apic will help finance this compassionate use trial and help us evolve this work into the expanded access, Phase I trial. Having an industry partner like Apic allows us to leverage your generosity and accelerate our work with high expectations for success at the clinical-trial-stage.
I also am pleased to report that in addition to our promising SOD1 work, we continue our efforts to bring new therapies to clinical trial targeting the C9 gene as well. Our work on C9 has been of particular interest and focus for the Angel Fund, for which we are so grateful. We are moving forward with our C9 initiative on a dual pronged approach. First, we are using our own, in-house antisense technology to silence the mutant C9 gene. Second, we are fortunate to have partnered with a Cambridge based biotech company, called Wave Life Sciences, to help them develop a novel type of product that also silences the C9 gene.
The past twelve months have proven to be an inflection point in my more than 30 years of studying ALS. Entering into these human clinical trials with innovative and promising new therapies represents the culmination of a lot of hard work by a talented and dedicated team at UMass Medical School and the Mass General Hospital. While we still have so much more work to do and many more miles to travel, I never have been more optimistic about the possibility of effectively treating genetic ALS – and eventually all forms of ALS.
There has never been a more exciting and promising time in ALS research.
One main area of focus for Dr. Brown and his team at UMass Medical School is the genetic basis of ALS and its implications for treatment.
Over the last year, the UMass team has identified several new ALS genes. An international consortium, spearheaded by Dr. John Landers at UMass (who works closely with Dr. Brown) has identified five new ALS genes, bringing the total to more than 50. Perhaps most importantly, each gene is a clue to the biology of ALS and to possible ALS treatments. One way to dissect these genes further is to develop fruit fly models using the ALS genes. This year alone, Dr. Fen-Biao Gao also at UMass has published several seminal studies about ALS genetics based on the fruit fly studies.
A major lesson is that ALS genes appear to cause disease by having a toxic influence on motor neurons. This suggests that reducing the activity of these genes may be beneficial. Fortunately, key discoveries in the technology to silence genes were made by investigators at UMass.
Working with those experts, and with the Gene Therapy Center at UMass, Dr. Brown has been able to “turn off” some of the defective ALS genes. This worked extremely well in mouse models of ALS and has proven to be safe in larger animals. Accordingly, the UMass team believes that we are closer than ever testing these approaches in humans.
At present, the UMass team is focusing its efforts on two major ALS genes, known as SOD1 and C9orf72 (the two most common ALS genes). However, a key point is that these experiments set the stage for a much broader program to shut down many other ALS genes. Moreover, this therapeutic strategy may also prove applicable in non-familial ALS.
Today, we as a community hold great hope that these studies, moving from genetics to targeted therapies, will slow the progression of ALS and provide substantial benefit to ALS patients and their families. The entire team at UMass Medical is deeply grateful to the Angel Fund for its continuing support of this research program.
Watch the video.
Robert Brown, Jr., D.Phil., M.D.